Journal of Clinical Endocrinology & Metabolism, Vol 72, 477-483, Copyright © 1991 by Endocrine Society

ARTICLES

Thyrotropin-secreting pituitary adenomas: report of seven cases

A Beckers, R Abs, C Mahler, JL Vandalem, G Pirens, G Hennen and A Stevenaert
Department of Endocrinology, University of Liege, Belgium.

Seven patients with hyperthyroidism due to a TSH-secreting pituitary macroadenoma have been observed of a total of 800 patients with pituitary tumors over a period of 15 yr. Serum TSH levels varied between 1.1-36.3 mU/L. The serum alpha-subunit level was low in 1 case, while in 4 other cases the concentration was elevated and varied between 3.7-7.8 micrograms/L. Serum TSH beta levels were normal in the 4 cases in which it was determined. Serum GH or PRL levels were elevated in 5 cases. In 1 patient the cosecretion of TSH, GH, and PRL was confirmed by immunocytochemical examination. Serum TSH and alpha- subunit responses to TRH, GnRH, CRF, GRF, dexamethasone, methimazole, T3, and bromocriptine administration were variable when studied. Serum TSH and alpha-subunit circadian rhythms were absent in 1 case and inverted in another. A serum alpha-subunit pulsatility without TSH pulses was observed in 1 patient. Five patients underwent transsphenoidal adenomectomy. Three of 4 patients operated on in our center were cured, but a recurrence of the adenoma was found in 1 of them after 5 yr. The fifth patient was not cured. Treatment with octreotide in 3 patients resulted in normalization of serum TSH, GH, and thyroid hormones levels. Cosecretion of PRL in 1 case and alpha- subunit in 2 cases was also inhibited. Partial tachyphylaxis occurred in 1 patient. In summary, heterogeneity in clinical presentation, hormonal expression, and therapeutic response appears to characterize these TSH-secreting adenomas.

This article has been cited by other articles:

				T. Kienitz, M. Quinkler, C. J Strasburger, and M. Ventz Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature Eur. J. Endocrinol., July 1, 2007; 157(1): 39 - 46. [Abstract] [Full Text] [PDF]

				D. Vezzosi, A. Bennet, P. Rochaix, F. Courbon, J. Selves, B. Pradere, L. Buscail, C. Susini, and P. Caron Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies Eur. J. Endocrinol., May 1, 2005; 152(5): 757 - 767. [Abstract] [Full Text] [PDF]

				P. Caron, S. Arlot, C. Bauters, P. Chanson, J.-M. Kuhn, M. Pugeat, R. Marechaud, C. Teutsch, E. Vidal, and P. Sassano Efficacy of the Long-Acting Octreotide Formulation (Octreotide-Lar) in Patients with Thyrotropin-Secreting Pituitary Adenomas J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2849 - 2853. [Abstract] [Full Text] [PDF]

				J. M. Kuhn, S. Arlot, H. Lefebvre, P. Caron, C. Cortet-Rudelli, F. Archambaud, P. Chanson, A. Tabarin, M. Goth, J. Blumberg, et al. Evaluation of the Treatment of Thyrotropin-Secreting Pituitary Adenomas with a Slow Release Formulation of the Somatostatin Analog Lanreotide J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1487 - 1491. [Abstract] [Full Text]

				F. Brucker-Davis, E. H. Oldfield, M. C. Skarulis, J. L. Doppman, and B. D. Weintraub Thyrotropin-Secreting Pituitary Tumors: Diagnostic Criteria, Thyroid Hormone Sensitivity, and Treatment Outcome in 25 Patients Followed at the National Institutes of Health J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 476 - 486. [Abstract] [Full Text]